Dharmatma Singh
Overview
Explore the profile of Dharmatma Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh A, Bhardwaj A, Sharma R, Kahlon B, Dhaliwal A, Singh D, et al.
Intest Res
. 2024 Nov;
PMID: 39523709
Background/aims: Accurate assessment of disease activity is crucial for effective management and treatment of ulcerative colitis (UC). This study evaluated the correlation between clinical, endoscopic, and histologic measures of disease...
2.
Singh A, Mahajan R, Midha V, Kaur K, Singh D, Kaur R, et al.
Dig Dis Sci
. 2024 Feb;
69(4):1389-1402.
PMID: 38358458
Background: Ulcerative proctitis (UP), though associated with high symptom burden and poor quality of life, is excluded from most of the randomized controlled trials in UC, including the OCTAVE trials....
3.
Singh A, Bhardwaj A, Tripathi A, Ranjan M, Singh D, Sachdeva A, et al.
Dig Dis Sci
. 2024 Jan;
69(3):775-790.
PMID: 38282185
Background: Patients with Inflammatory bowel disease (IBD) are susceptible to psychiatric co-morbidities. We aimed to ascertain the burden of anxiety, depression, and perceived stress in patients with IBD from north...
4.
Singh A, Goyal M, Midha V, Mahajan R, Kaur K, Gupta Y, et al.
Am J Gastroenterol
. 2023 Dec;
119(7):1365-1372.
PMID: 38131615
Introduction: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%-40% of the patients are refractory to corticosteroids. We investigated whether addition...
5.
Singh A, Midha V, Kaur K, Mahajan R, Singh D, Kaur R, et al.
J Crohns Colitis
. 2023 Sep;
18(2):300-307.
PMID: 37656880
Background: Oral corticosteroids are first-line agents to induce remission in moderately active ulcerative colitis [UC], but are associated with adverse effects. We compared the efficacy and safety of tofacitinib and...
6.
Singh A, Kakkar C, Garg S, Arora K, Midha V, Mahajan R, et al.
Indian J Gastroenterol
. 2023 Aug;
42(5):668-676.
PMID: 37548863
Background: Fistulizing perianal Crohn's disease (CD) is a debilitating condition associated with significant morbidity and reduction in the quality of life. Magnetic resonance imaging (MRI) of the pelvis is the...
7.
Kakkar C, Singh A, Mahajan R, Midha V, Goyal S, Narang V, et al.
Indian J Gastroenterol
. 2022 Nov;
41(5):465-474.
PMID: 36357600
Background: Magnetic resonance enterography (MRE) has emerged as a novel tool for the assessment of disease activity in Crohn's disease (CD). Real world data from Indian subcontinent on performance of...
8.
Singh A, Gupta Y, Dhaliwal A, Kahlon B, Bansal V, Mahajan R, et al.
Intest Res
. 2022 Oct;
21(3):375-384.
PMID: 36245342
Background/aims: The inflammatory bowel disease (IBD)-disk is a validated, visual, 10-item, self-administered questionnaire used to evaluate IBD-related disability. The present study aimed to evaluate IBD-disk in assessment of IBD daily...
9.
Singh A, Mahajan R, Kahlon B, Dhaliwal A, Midha V, Mehta V, et al.
Indian J Gastroenterol
. 2022 Sep;
41(4):389-396.
PMID: 36121613
Background: Fecal microbiome transfer (FMT) targeting gut microbiome dysbiosis is an emerging therapy for ulcerative colitis (UC). There is however no consensus on protocols for performing FMT in UC, especially...
10.
Singh A, Midha V, Mahajan R, Verma S, Kakkar C, Grover J, et al.
Dig Dis Sci
. 2022 Sep;
68(2):580-595.
PMID: 36064826
Background: Inflammatory bowel disease (IBD) is associated with an increased risk of malnutrition and sarcopenia. Aims: To evaluate the nutritional status of patients with IBD and determine the threshold values...